AzTrials
AzTrials

Squamous Cell CarcinomaNCT00364715

Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer

An observational study of Squamous Cell Carcinoma, run by National Taiwan University Hospital at 1 site in Taiwan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Recent studies have shown that dysregulation of ANXA1 expression are associated with tumorigenesis. Overexpression of ANXA1 protein is found in a wide variety of human tumors, such as breast 10, liver 11, pancreatic cancer14 and glial tumors15. Read more about this study

Who is it for?
Ages 26 to 85 years
Conditions the study is for
Squamous Cell Carcinoma
How many people
Not given
Where
1 siteTaiwan
Study dates
Jan 2005to Dec 2005
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 26 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • noraml, dysplasia, SCC

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Taiwan1 site
  • National Taiwan University Hospital

    Taipei, 100

Other trials in Taiwan

About this study

Recent studies have shown that dysregulation of ANXA1 expression are associated with tumorigenesis. Overexpression of ANXA1 protein is found in a wide variety of human tumors, such as breast 10, liver 11, pancreatic cancer14 and glial tumors15. In contrast, reduced levels of ANXA1 protein expression have been reported in ESCC4, 5, gastric6, breast7, head and neck SCC8 and prostate cancer9. No previous study on ANXA1 protein expression has been reported in the cancer of oral cavity. Furthermore, although alterations in annexin expression in different types of tumors have been described, no correlation has been established between ANXA1 and overall patient survival yet.

ANXA1 is a major cellular substrate of the oncogenic tyrosine kinases such as EGF receptor and hepatocyte growth factor (HGF) receptor, c-met. Previously, we have shown that expression of HGF and c-met is significantly associated with the progression of OSCC in Taiwan. Kermorgant et al. recently showed that PKC controls HGF-dependent c-met traffic, signaling and cell migration. Prior study indicate that the mitogen phorbol-12-myristate 13-acetate (PMA) induced ANXA1 nuclear translocation in a PKCdelta-dependent manner and ANXA1 nuclear translocation may participate in the regulation of cellular proliferation and the differentiation. However, it is not known whether HGF can induce ANXA1 nuclear translocation or not and how this relates to the pathogenesis of oral SCC.

In this study we aimed to investigate whether HGF induced the translocation of ANXA1 protein to the nucleus in OSCC cells and the role(s) of ANXA1 nuclear localization in the carcinogenesis of OSCC using an immunohistochemical technique. The data suggest a novel mechanism for HGF-induced ANXA1 protein nuclear translocation that may play an important role in the pathogenesis and prognosis in oral SCCs.

Read the detailed description

MATERIAL AND METHODS

After approval by the Hospital Review Board, we obtained formalin-fixed, paraffin-embedded specimens from 115 patients with primary oral SCC and 66 patients with oral ED at the Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. Diagnosis of oral SCC and ED was based on histological examination of hematoxylin and eosin-stained tissue sections. All patients received total surgical excision of the lesions at the Department of Oral and Maxillofacial Surgery or Department of Otolaryngology, National Taiwan University Hospital during the period from 1997 to 2004. Specimens were obtained from either incisional biopsies or total surgical excision of the lesions. If lymph node was diagnosed as positive for SCC, neck dissection and postoperative radiation therapy were also included in the treatment protocol. No patient had received any cancer therapy before initial biopsies. Details of the patients' oral habits, including daily consumption of AQs, cigarettes, and alcohol as well as the duration of these habits, were also recorded in the medical chart. Twenty biopsy specimens of normal oral mucosa (NOM) were obtained from non-AQ-chewers and non-smokers during extraction of impacted permanent lower third molars after obtaining informed consent, and used as the healthy controls.

Cell culture Dulbecco's modifed Eagle's medium (DMEM), and fetal bovine serum (FBS) were purchased from Life Technologies, Inc. (Gaithersburg, MD,USA). PD98059, Ly294002, SB203580 and Hepatocyte growth factor (HGF) were products of Sigma (St Louis, MO, USA). Anti-ANX-1 monoclonal antibody was purchased from BD Biosciences (Lexington, KY, USA). Cell culture SAS cells were maintained in DMEM supplemented with 10% heat-inactivated FBS, penicillin (100 UAmL)1), and streptomycin (100 lgAmL)1) at 37 o C under 5% CO2 atmosphere. For Western blot analysis, cells were seeded into 10 cm dishes at 2 x 106 cells per dish. After 18-24 hr, cells were further grown in the same medium supplemented without FBS for 24 h. Serum-starved cells were treated with HGF in the indicated times. For immunostaining, 2 x 105 cells grown on cover slides (22 x 22 mm) were starved for 24 h before stimulation with HGF.

Pre-treatment with PD098059, Ly294002 and SB203580 The cells were plated overnight in complete medium and then washed. The cells cultured in serum-free DMEM were pre-treated with 50M PD098059 (inhibitor of ERK), 30 M Ly294002( inhibitor of PI-3 kinase) and 20 M SB203580(inhibitor of p38) for 3 hrs respectively, and then they were treated with 40ng HGF for 3hrs. The cells were checked by immunohistochemistry and Western blot with ANXA1 antibody.

Immunocytochemistry(IHC) Formalin-fixed, paraffin-embedded tumor samples were assessed for annexin A1 expression.The IHC procedures was followed as the reference18, The monoclonal primary antibody anti-Annexin AI(1:600 dilution), directed against the the N-terminus of annexin 1 were obtained from a signal source (BD Biosciences). Protein translocation as determined by two pathologists (Jeng and Lin) using immunohistochemistry was scored as negative (score 0), positive (score 1) and cytoplasmic protein expression was scored as negative (score 0), weak (score 1), moderate (score 2), or strong (score 3) using a system that has been previously validated.

SAS cells grown on cover slides were fixed with 3.7% paraformaldehyde for 15 min and permeabilized with 0.2% Triton X-100 in PBS (0.58M Na2HPO4, 0.17 M Na H2PO4, 0.68 M NaCl, pH=7.4)(PBST) for 5 min. After washing the cells with PBST three times, the cells were blocked for 30 min in PBS containing 1% bovine serum albumin. Immunostaining was performed by incubation with anti-ANX-1 monoclonal antibody (1:800 dilution) for 2h. After washing the cells with PBST three times, the cells were incubated with TRITC-conjugated rabbit anti-(mouse IgG) Ig for 1 h. Cover slides were washed with PBST, mounted, and examined using a Leica TCS SP2 Confocal microscope (Leica Microsystems, Wetzlar GmBH, Germany).

Cell fractionation SAS cells were seeded into 10cm dishes at 2x 106 cells/dish and cultured in DMEM for 18-24 h. The cells were starved for 24 h in serum-free media. After treatment with HGF for a given time, the cells were harvested and washed with ice-cold PBS. The cells were then resuspended in 100 lL of lysis buffer (10 mM Hepes, 10 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 1% NP-40, 0.5 mM phenylmethylsulfonyl uoride, 0.1 mM dithiothreitol, 0.1 mM sodium orthovanadate, and protease inhibitors) and incubated on ice for 10 min. The nuclei were collected by centrifugation at 2000 g for 5 min at 4 o C. The supernatant was collected as a cytosolic fraction. Protein concentration of each sample was determined.

Evalution of annexin A1 Protein Expression The distributions of ANXA1 expression in four categories (0-25%, 26-50%, 51-75% and 76-100%) with nuclear translocation were firstly showed by clinicopathological parameters of the oral ED and SCCs and the correlations between mean levels of expression and these clinicopathological parameters were further examined using ANOVA. The Kaplan-Meier product-limit method was used to assess the prognostic significance of the ANXA1 nuclear staining in cancer cells as well as other clinicopathological parameters. Comparison of cumulative survival between groups was performed using the log-rank test with the Statistica program (StatSoft Inc., USA). Multivariable analyses were performed with Cox regression model to assess additional prognostic values of the different variables using SAS 8.0 (SAS Institute Inc., USA). A P-value of less than 0.05 was considered as statistically significant.

Keywords
Nuclear localization, annexin A1, oral SCC
Medical subject headings
Carcinoma, Squamous Cell

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Aug 2006 (estimated)
  2. Study startJan 2005
  3. Study completionDec 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Other
IDs, dates and publications
ClinicalTrials.gov ID
NCT00364715
Sponsor's protocol ID
9561702012
Status last verified
Aug 2006
First submitted
15 Aug 2006
Last updated
17 Aug 2006
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Squamous Cell Carcinoma, run by National Taiwan University Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Aug 2006. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2006.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in